Study Confirms Lubrizol’s MAGSHAPE™ Enhances Magnesium Absorption
Lubrizol’s MAGSHAPE™ microcapsules, a micronized and microencapsulated form of magnesium, have been shown in a recent study to significantly enhance magnesium absorption compared to other widely used magnesium sources. The clinical study, published in the journal Nutrients, was conducted by researchers from Bionos Biotech SL and Lubrizol Nutraceuticals. This groundbreaking study highlights the superior bioavailability and reduced side effects of MAGSHAPE™, offering an innovative solution for individuals seeking science-backed magnesium products.
The study also supports the findings of a prior consumer survey where participants expressed a clear preference for MAGSHAPE™ microcapsules over four other magnesium supplement options, citing its better taste and texture.
The clinical study in question was a double-blind, randomized, cross-over trial involving 40 healthy volunteers. The study aimed to compare the effects of various magnesium supplements on blood plasma magnesium (Mg) levels, including magnesium oxide, magnesium citrate, magnesium bisglycinate, and MAGSHAPE™ microcapsules. Participants were given different magnesium supplements under controlled conditions, and their blood plasma magnesium levels were measured at several intervals: at baseline, one hour, four hours, and six hours after taking each supplement.
One of the study’s secondary goals was to assess the prevalence of side effects commonly associated with magnesium supplementation, such as digestive discomfort, which can deter people from using magnesium products. The results of the study revealed that MAGSHAPE™ microcapsules not only elevated blood plasma magnesium levels at all measured time points but also maintained these elevated levels for up to six hours after consumption. In comparison, the other magnesium sources did not produce the same sustained increase in magnesium levels.
Participants in the study also reported fewer adverse effects when using MAGSHAPE™ microcapsules. They experienced fewer issues with intestinal motility and gastric heaviness compared to the other magnesium supplements evaluated. These findings indicate that the unique formulation of MAGSHAPE™ microcapsules reduces discomfort while improving the overall effectiveness of magnesium supplementation.
“The results from this study demonstrate the potential of MAGSHAPE™ to transform magnesium supplementation,” said Isabel Gomez, Marketing Manager at Lubrizol Nutraceuticals. “The study specifically compared MAGSHAPE™ microencapsulated magnesium oxide to raw magnesium oxide, and the significant improvements in absorption and side effects were made possible by our innovative microencapsulation technology.”
The improved absorption of magnesium with MAGSHAPE™ has important implications for a variety of health concerns. “Maintaining adequate magnesium levels is essential for overall health,” said Alan Connolly, R&D Manager at Lubrizol Nutraceuticals. “The study suggests that MAGSHAPE™ can benefit individuals looking to enhance their muscle recovery, improve sleep patterns, or maintain magnesium levels for general well-being.”
The study’s findings on the gastric tolerability of MAGSHAPE™ are particularly notable. Many magnesium supplements can cause digestive discomfort, but the microencapsulation process in MAGSHAPE™ mitigates these issues, making it a more comfortable option for long-term use. This makes it an ideal choice for people who are sensitive to other magnesium supplements but still wish to experience the health benefits of magnesium.
Teresa Negra, a new business development specialist at Lubrizol Nutraceuticals, noted the study’s key conclusions: “The improved gastric tolerability, along with the statistically significant and sustained magnesium absorption profile, makes MAGSHAPE™ a strong candidate for individuals seeking to benefit from adequate magnesium levels.”
Lubrizol’s MAGSHAPE™ technology offers a promising solution to those seeking an effective, well-tolerated magnesium supplement. With better absorption, fewer side effects, and improved overall bioavailability, MAGSHAPE™ could become a preferred choice for consumers looking to support their health.
About The Lubrizol Corporation
The Lubrizol Corporation, a Berkshire Hathaway company, is a science-based specialty chemicals company that provides sustainable solutions to enhance mobility, improve well-being, and advance modern life. Lubrizol operates more than 100 manufacturing facilities and technical offices globally and employs nearly 8,000 people. Founded in 1928, Lubrizol continues to lead in innovation, creating breakthrough solutions at the intersection of science, market needs, and business success.
